These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 25655110)

  • 1. Weight regain after discontinuation of topiramate treatment in patients with migraine: a prospective observational study.
    Verrotti A; Parisi P; Agostinelli S; Loiacono G; Marra F; Coppola G; Pisani LR; Gorgone G; Striano P; Pisani F; Belcastro V
    CNS Drugs; 2015 Feb; 29(2):163-9. PubMed ID: 25655110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Weight reducing and metabolic effects of topiramate in patients with migraine--an observational study.
    Schütt M; Brinkhoff J; Drenckhan M; Lehnert H; Sommer C
    Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):449-52. PubMed ID: 20200812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topiramate weight loss in migraine patients.
    Alberici A; Borroni B; Manelli F; Griffini S; Zavarise P; Padovani A; Dalla Volta G
    J Neurol Sci; 2009 Mar; 278(1-2):64-5. PubMed ID: 19084843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority trial in adult migraineurs.
    Dodick DW; Freitag F; Banks J; Saper J; Xiang J; Rupnow M; Biondi D; Greenberg SJ; Hulihan J;
    Clin Ther; 2009 Mar; 31(3):542-59. PubMed ID: 19393844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension.
    Tremblay A; Chaput JP; Bérubé-Parent S; Prud'homme D; Leblanc C; Alméras N; Després JP
    Eur J Clin Pharmacol; 2007 Feb; 63(2):123-34. PubMed ID: 17200837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Topiramate, nutrition and weight change: a prospective study.
    Klein KM; Theisen F; Knake S; Oertel WH; Hebebrand J; Rosenow F; Hamer HM
    J Neurol Neurosurg Psychiatry; 2008 May; 79(5):590-3. PubMed ID: 18077476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and tolerability of topiramate 200 mg/d in the prevention of migraine with/without aura in adults: a randomized, placebo-controlled, double-blind, 12-week pilot study.
    Silberstein SD; Hulihan J; Karim MR; Wu SC; Jordan D; Karvois D; Kamin M
    Clin Ther; 2006 Jul; 28(7):1002-11. PubMed ID: 16990078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topiramate vs divalproex sodium in the preventive treatment of migraine: a prospective "real-world" study.
    Krymchantowski AV; Jevoux CC
    Headache; 2011 Apr; 51(4):554-8. PubMed ID: 21457240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of weight loss in adults with topiramate-treated epilepsy.
    Ben-Menachem E; Axelsen M; Johanson EH; Stagge A; Smith U
    Obes Res; 2003 Apr; 11(4):556-62. PubMed ID: 12690085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A low TSH profile predicts olanzapine-induced weight gain and relief by adjunctive topiramate in healthy male volunteers.
    Evers SS; van Vliet A; van Vugt B; Scheurink AJ; van Dijk G
    Psychoneuroendocrinology; 2016 Apr; 66():101-10. PubMed ID: 26802597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of topiramate in migraine prevention: results from a pharmacoeconomic model of topiramate treatment.
    Brown JS; Papadopoulos G; Neumann PJ; Friedman M; Miller JD; Menzin J
    Headache; 2005 Sep; 45(8):1012-22. PubMed ID: 16109115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topiramate in Migraine Prevention: A 2016 Perspective.
    Silberstein SD
    Headache; 2017 Jan; 57(1):165-178. PubMed ID: 27902848
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weight change and clinical markers of cardiovascular disease risk during preventive treatment of migraine.
    Bigal ME; Lipton RB; Biondi DM; Xiang J; Hulihan J
    Cephalalgia; 2009 Nov; 29(11):1188-96. PubMed ID: 19558539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal factor analysis reveals a distinct clustering of cardiometabolic improvements during intensive, short-term dietary and exercise intervention in obese children and adolescents.
    Hobkirk JP; King RF; Gately P; Pemberton P; Smith A; Barth JH; Carroll S
    Metab Syndr Relat Disord; 2012 Feb; 10(1):20-5. PubMed ID: 21936669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in cardiovascular risk associated with phentermine and topiramate extended-release in participants with comorbidities and a body mass index ≥27 kg/m(2).
    Davidson MH; Tonstad S; Oparil S; Schwiers M; Day WW; Bowden CH
    Am J Cardiol; 2013 Apr; 111(8):1131-8. PubMed ID: 23375187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP).
    Allison DB; Gadde KM; Garvey WT; Peterson CA; Schwiers ML; Najarian T; Tam PY; Troupin B; Day WW
    Obesity (Silver Spring); 2012 Feb; 20(2):330-42. PubMed ID: 22051941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: a double-blind, placebo-controlled trial.
    Narula PK; Rehan HS; Unni KE; Gupta N
    Schizophr Res; 2010 May; 118(1-3):218-23. PubMed ID: 20207521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Waist circumference provides an indication of numerous cardiometabolic risk factors in adults with cerebral palsy.
    Ryan JM; Crowley VE; Hensey O; McGahey A; Gormley J
    Arch Phys Med Rehabil; 2014 Aug; 95(8):1540-6. PubMed ID: 24742941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of topiramate use on body composition and resting metabolic rate in migraine patients.
    Yaman M; Ucok K; Demirbas H; Genc A; Oruc S; Karabacak H; Koyuncu G
    Neurol Sci; 2013 Feb; 34(2):225-9. PubMed ID: 22391675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anthropometric indexes, insulin resistance, and serum leptin and lipid levels in women with cryptogenic epilepsy receiving topiramate treatment.
    Genc BO; Dogan EA; Dogan U; Genc E
    J Clin Neurosci; 2010 Oct; 17(10):1256-9. PubMed ID: 20598547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.